| A Study of CS060380 Tablets in Patients With MASH and Obesity (NCT07466017) | Cascade Pharmaceuticals, Inc | 2026-04-02 |
| Drug Interaction and Food Effect Study of CS0159 (NCT07429331) | Cascade Pharmaceuticals, Inc | 2026-03-09 |
| A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA (NCT07282353) | Cascade Pharmaceuticals, Inc | 2025-12-01 |
| Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) (NCT07198386) | Cascade Pharmaceuticals, Inc | 2025-09-30 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects (NCT06485245) | Cascade Pharmaceuticals, Inc | 2025-04-22 |
| A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury (NCT06888115) | Cascade Pharmaceuticals, Inc | 2025-03-13 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects (NCT06573528) | Cascade Pharmaceuticals, Inc | 2024-09-03 |
| Study of [14C]CS0159 in China Healthy Subjects (NCT06098027) | Cascade Pharmaceuticals, Inc | 2023-10-23 |
| CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis) (NCT05896137) | Cascade Pharmaceuticals, Inc | 2023-08-07 |
| CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) (NCT05896124) | Cascade Pharmaceuticals, Inc | 2023-08-07 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH (NCT05591079) | Cascade Pharmaceuticals, Inc | 2023-02-10 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects (NCT05624294) | Cascade Pharmaceuticals, Inc | 2022-12-19 |
| Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 (NCT05082779) | Cascade Pharmaceuticals, Inc | 2021-10-26 |